The Food and Drug Administration, is on its way to lift its ban on the stem cell trial on spinal cord injury. The California biotech Geron Corp. is expected to do the pioneering research by early next year.
The phase 1 trial would test whether it is safe to inject nerve cells into the site of a spinal cord injury. Geron president and CEO Tom Okarma said there’s no indication that politics were behind the FDA’s delayed approval, according to The Scientist. He made his remarks at the New York Stem Cell Foundation conference at Rockefeller University last Wednesday.
An FDA spokeswoman said the agency doesn’t comment on products under development.
Source: Scientific American